Novel Procedure Demonstrates Potential to Lower Cholesterol and Manage Heart Disease Without Medication
London, UK – November 9, 2025 – A groundbreaking treatment, currently undergoing clinical trials, offers a potential path to managing heart disease and substantially reducing “bad” cholesterol levels without relying on customary pharmaceutical interventions or restrictive diets. Early results indicate the procedure can cut LDL cholesterol – a key contributor to heart disease – by as much as 50%, presenting a novel approach for the millions globally affected by cardiovascular ailments.
Heart disease remains the leading cause of death worldwide, impacting an estimated 17.9 million lives annually, according to the World Health Organization. Current management strategies often involve lifelong medication and significant lifestyle changes, posing challenges for patient adherence and long-term efficacy. This new treatment,developed by researchers at King’s College London,targets a specific protein in the liver responsible for cholesterol regulation,offering a potentially more enduring and less burdensome solution.The research, published in The Lancet on November 8, 2025, details a minimally invasive procedure utilizing targeted gene editing technology.
The treatment involves a single injection containing modified mRNA molecules designed to instruct liver cells to produce a protein that binds to and neutralizes PCSK9, a protein that prevents the liver from removing LDL cholesterol from the bloodstream. In a Phase 1 clinical trial involving 30 participants with high cholesterol levels, the procedure demonstrated a consistent and significant reduction in LDL cholesterol within four weeks of treatment, with effects lasting for at least six months.
“We are incredibly encouraged by these initial findings,” stated Dr. Amelia Stone, lead researcher on the project. “The ability to significantly lower cholesterol with a single treatment, without the need for ongoing medication, could revolutionize the way we approach heart disease management.”
Researchers emphasize that the treatment is still in its early stages of growth and requires further investigation through larger, randomized controlled trials to confirm its long-term safety and efficacy. Phase 2 trials, involving a broader patient population, are scheduled to begin in early 2026 across multiple European sites. If prosperous, this innovative approach could offer a new hope for individuals seeking to proactively manage their heart health and reduce their risk of cardiovascular events.